Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Esbriet, Pirespa
Pirfenidone is an antifibrotic drug used to treat idiopathic pulmonary fibrosis (IPF), a chronic and progressive lung disease characterized by scarring and stiffening of the lung tissue. It is thought to work by reducing the production of growth factors and collagen, which are involved in the fibrosis process. Pirfenidone is classified as an antifibrotic agent and belongs to the pyridine class of chemical compounds.
For the treatment of idiopathic pulmonary fibrosis (IPF).
Outcome:
Increased pirfenidone levels
Mechanism:
Inhibition of CYP1A2 metabolism
Outcome:
Slightly decreased pirfenidone levels
Mechanism:
Induction of CYP1A2 metabolism
Outcome:
Potential for slightly decreased pirfenidone absorption
Mechanism:
Changes in gastric pH
Most likely new formulation: Slow-release formulation (Year: 2026, 75% confidence)
Based on current clinical trial data and post-market surveillance, pirfenidone is expected to maintain its current regulatory status for IPF treatment with a high likelihood (90%) of remaining on market.
Antifibrotic
Pyridine